Merck
  • Home
  • Search Results
  • MiR-133b targets Sox9 to control pathogenesis and metastasis of breast cancer.

MiR-133b targets Sox9 to control pathogenesis and metastasis of breast cancer.

Cell death & disease (2018-07-05)
Qiu-Yu Wang, Ci-Xiang Zhou, Meng-Na Zhan, Jun Tang, Chen-Long Wang, Cheng-Ning Ma, Ming He, Guo-Qiang Chen, Jian-Rong He, Qian Zhao
ABSTRACT

The miR-133b, a commonly recognized muscle-specific miRNA, was reported to be deregulated in many kinds of cancers. However, its potential roles in tumorigenesis remain greatly elusive. Herein, we demonstrate that miR-133b is significantly suppressed in human breast cancer specimens, which is reversely correlated to histological grade of the cancer. Ectopic expression of miR-133b suppresses clonogenic ability and metastasis-relevant traits in vitro, as well as carcinogenesis and pulmonary metastasis in vivo. Further studies have identified Sox9, c-MET, and WAVE2 as direct targets of miR-133b, in which Sox9 contributes to all miR-133b-endowed effects including cell proliferation, colony formation, as well as cell migration and invasion in vitro. Moreover, re-expression of Sox9 reverses miR-133b-mediated metastasis suppression in vivo. Taken together, these findings highlight an important role for miR-133b in the regulation of tumorigenesis and metastatic potential of breast cancer and suggest a potential application of miR-133b in cancer treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Sox9 Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Insulin from bovine pancreas, ≥25 USP units/mg (HPLC), powder